^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer
Published date:
08/08/2023
Excerpt:
Median age of patients was 65 years (IQR 57-72), 65.8% were females, 80.7% never-smokers, 91.3% with ECOG 0-1 at start of osimertinib, and 97.5% had adenocarcinoma histology…Majority had sensitizing EGFR exon 19 deletion (exon 19+) (55.9%) and exon 21 mutations (exon 21+) (36.6%)…mOS for exon 19+ patients was 37.0 (95% CI 32.2-52.2) months and 25.1 (95% CI 18.6-38.1) months for exon 21+ (p=0.015)...Osimertinib is an effective first-line treatment in Asian patients with advanced EGFRm+ NSCLC with durable OS, PFS and TTF, comparable with reported data.
Source:
Title:
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
Published date:
02/16/2023
Excerpt:
Patients with a measurable stage IIA-IIIB (T3-4 N2) lung adenocarcinoma and EGFR exon 19 and/or 21 mutations were enrolled….The ORR was 71.1 % (27/38) (95 % confidence interval: 55.2-83.0) in 38 patients who completed the 6-week osimertinib treatment….The third-generation EGFR TKI osimertinib, with satisfying efficacy and acceptable safety profile, could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC.
DOI:
10.1016/j.lungcan.2023.02.011
